Targeting Fibrosis to Preserve hand function
Modulating immune-fibrotic pathways to delay progression and reduce recurrence
Progressive fibrosis in Dupuytren’s contracture leads to finger contractures and functional impairment. Ventoux Biosciences is developing VEN‑201 as a potential first‑in‑class disease‑modifying therapy to delay disease progression and reduce post‑intervention recurrence. By targeting immune‑fibrotic mechanisms, VEN‑201 aims to preserve hand function and improve long‑term outcomes for patients.
Dupuytren's Disease
Our Mission to Transform Treatment
Dupuytren’s is a chronic, progressive, immune‑fibrotic disease of the hand that leads to finger contractures and impaired function. Current treatment options are largely limited to later‑stage or more severe disease, leaving patients without effective therapies to slow progression in earlier stages.
Even when interventions such as fasciectomy or collagenase injections are performed, recurrence rates remain high, underscoring the need for additional options, adjunct to the intervention, to improve long‑term outcomes.
Ventoux Biosciences is advancing VEN‑201 as a potential first‑line, first-in-class, disease‑modifying therapy designed to intervene earlier in the fibrotic cascade. By modulating immune‑fibrotic pathways, VEN‑201 aims to delay disease progression, reduce recurrence after surgical or non‑surgical interventions, and preserve long‑term hand function.
How Does Dupuytren's Impact Patients
Decreased / Loss of Hand Function
Disease causes fingers to bend inwards towards the palm. Affected fingers can not straighten, thus significant impact on hand function.
Loss of Hand Mobility
Fibrosis from Dupuytren's may also move laterally across the palm, impacting ability to spread hand / fingers.
Activities of Daily Living
Typically simple activities can be difficult or impossible for Dupuytren's patients - from shaking hands to putting on gloves or throwing a football.
Reduced Quality of Life (QoL)
Dupuytren's disease affects both performance of activities and patient QoL.
Work Loss / Economic Implications
Loss of hand function / range or hand motion are key limiters for some patients to perform work tasks.
Pain
Patients with Dupuytren's may also experience pain, tenderness, burning, pressure / tension, tightness, and itching.
Significant unmet Medical need & Large addressable population
>30 million
Estimated Prevalence in United States and Europe
Up to 85%
Patient Post Operative Disease Recurrence, 5-years
o
Approved first-line, disease modifying pharmacologic treatment options
